US 11,806,350 B2
Prevention and/or treatment of CNS disorders
Kyung-Sun Kim, Hwaseong-si (KR); Jeong-Ah Kim, Hwaseong-si (KR); An-Na Moon, Hwaseong-si (KR); Dong-Keun Song, Hwaseong-si (KR); Yoon-Suk Lee, Hwaseong-si (KR); and Ju-Young Jung, Hwaseong-si (KR)
Assigned to ILDONG PHARMACEUTICAL CO., LTD., Seoul (KR)
Filed by ILDONG PHARMACEUTICAL CO., LTD., Seoul (KR)
Filed on Nov. 17, 2021, as Appl. No. 17/528,342.
Claims priority of provisional application 63/115,972, filed on Nov. 19, 2020.
Prior Publication US 2022/0152034 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01)
CPC A61K 31/519 (2013.01) 16 Claims
 
1. A method of treating a subject with a central nerve system (CNS) disorder or neurodegenerative disorder, comprising administering an effective amount of a compound of formula (II):

OG Complex Work Unit Chemistry
R1 is selected from (C1-C8)alkyl, substituted (C1-C8)alkyl, (C2-C8)alkenyl, substituted (C2-C8)alkenyl, (C2-C8)alkynyl, substituted (C2-C8)alkynyl, (C1-C3)haloalkyl, (C1-C8)alkoxy, substituted (C1-C8)alkoxy, —CONH2, substituted amido, —NH2, substituted amino, —CO2H, cyano, halogen, hydroxyl, —NO2, —SO3H, —SO2NH2, substituted sulfonamide, and thiol;
R2 to R9 are independently selected from H, (C1-C8)alkyl, substituted (C1-C8)alkyl, (C2-C8)alkenyl, substituted (C2-C8)alkenyl, (C2-C8)alkynyl, substituted (C2-C8)alkynyl, (C1-C3)haloalkyl, (C1-C8)alkoxy, substituted (C1-C8)alkoxy, —CONH2, substituted amido, —NH2, substituted amino, —CO2H, cyano, halogen, hydroxyl, —NO2, —SO3H, —SO2NH2, substituted sulfonamide, and thiol,
or a solvate, a hydrate, a prodrug, and/or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof,
to the subject.